| __timestamp | HUTCHMED (China) Limited | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 33472000 | 46425000 |
| Thursday, January 1, 2015 | 47368000 | 81491000 |
| Friday, January 1, 2016 | 66871000 | 94291000 |
| Sunday, January 1, 2017 | 50675000 | 121827000 |
| Monday, January 1, 2018 | 78821000 | 160524000 |
| Tuesday, January 1, 2019 | 91944000 | 200000000 |
| Wednesday, January 1, 2020 | 111234000 | 275000000 |
| Friday, January 1, 2021 | 207447000 | 328100000 |
| Saturday, January 1, 2022 | 267587000 | 463800000 |
| Sunday, January 1, 2023 | 303055000 | 565000000 |
| Monday, January 1, 2024 | 731100000 |
In the ever-evolving landscape of biotechnology, innovation is the key to staying ahead. Neurocrine Biosciences, Inc. and HUTCHMED (China) Limited have been at the forefront of this race, with their research and development (R&D) spending reflecting their commitment to innovation. Over the past decade, Neurocrine Biosciences has consistently outpaced HUTCHMED in R&D investment, with a notable 142% increase from 2014 to 2023. In 2023 alone, Neurocrine's R&D expenses reached a staggering 565 million, nearly doubling HUTCHMED's 303 million. This trend underscores Neurocrine's strategic focus on pioneering advancements in neuroscience. Meanwhile, HUTCHMED has shown a commendable growth trajectory, with a 806% increase in R&D spending since 2014, highlighting its dedication to expanding its oncology and immunology pipeline. As these companies continue to prioritize innovation, their R&D investments will likely shape the future of healthcare.
Who Prioritizes Innovation? R&D Spending Compared for AbbVie Inc. and Neurocrine Biosciences, Inc.
Research and Development Expenses Breakdown: Pfizer Inc. vs HUTCHMED (China) Limited
Vertex Pharmaceuticals Incorporated or Neurocrine Biosciences, Inc.: Who Invests More in Innovation?
Regeneron Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Verona Pharma plc
Research and Development Expenses Breakdown: Neurocrine Biosciences, Inc. vs Amicus Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Soleno Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Novavax, Inc.
Dr. Reddy's Laboratories Limited vs HUTCHMED (China) Limited: Strategic Focus on R&D Spending
Analyzing R&D Budgets: Bausch Health Companies Inc. vs HUTCHMED (China) Limited
R&D Insights: How HUTCHMED (China) Limited and Mesoblast Limited Allocate Funds